Hybio Pharmaceutical Co (SZSE:300199) 3-Year Revenue Growth Rate : -14.60% (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hybio Pharmaceutical Co 3-Year Revenue Growth Rate?

Hybio Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was ¥0.21.

During the past 12 months, Hybio Pharmaceutical Co's average Revenue per Share Growth Rate was -37.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -14.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -12.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Hybio Pharmaceutical Co was 45.60% per year. The lowest was -22.50% per year. And the median was 13.55% per year.

Competitive Comparison of Hybio Pharmaceutical Co's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hybio Pharmaceutical Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hybio Pharmaceutical Co's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hybio Pharmaceutical Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Hybio Pharmaceutical Co's 3-Year Revenue Growth Rate falls into.

Hybio Pharmaceutical Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Hybio Pharmaceutical Co (SZSE:300199) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Hybio Pharmaceutical Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Hybio Pharmaceutical Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hybio Pharmaceutical Co (SZSE:300199) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hybio Pharmaceutical Co Ltd (SZSE:300199) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

N/A

Address

4th Floor, Office Building, Hanyu Biomedical Park, Middle District, High-tech Industrial Park, Nanshan District, Guangdong Province, Shenzhen, CHN, 518057

Website

http://www.hybio.com.cn

Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.

Hybio Pharmaceutical Co (SZSE:300199) Headlines

No Headlines